Lack of tolerable treatment options for patients with schizophrenia

References

• National Institute of Mental HealthNumbers count: mental disorders in AmericaBethesda, MDNational Institute of Mental Health2013 Available from: http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america/index.shtml#SchizophreniaAccessed March 6, 2015
   Google Scholar
• US Census BureauAge and sex composition: 2010 (C2010BR-03)Washington, DCUS Census Bureau2011 Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdfAccessed March 6, 2015
   Google Scholar
• SchoepfDUppalHPotluriRHeunRPhysical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissionsEur Arch Psychiatry Clin Neurosci201426432823942824
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
   PubMed Web of Science ®Google Scholar
• MuenchJHamerAMAdverse effects of antipsychotic medicationsAm Fam Physician20108161762220187598
   PubMed Web of Science ®Google Scholar
• BruijnzeelDSuryadevaraUTandonRAntipsychotic treatment of schizophrenia: an updateAsian J Psychiatr2014113725216917
   PubMedGoogle Scholar
• ChaDSMcIntyreRSTreatment-emergent adverse events associated with atypical antipsychoticsExpert Opin Pharmacother2012131587159822304541
   PubMed Web of Science ®Google Scholar
• BasuAMeltzerHYTying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugsJ Comp Eff Res20121217118024237376
   PubMed Web of Science ®Google Scholar
• HermesEDSernyakMRosenheckRImpact of a program encouraging the use of generic antipsychoticsAm J Manag Care2012188307314
   PubMed Web of Science ®Google Scholar
• SmithKJBaikSHReynoldsCFRollmanBLZhangYCost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorderAm J Manag Care20131925563
   PubMed Web of Science ®Google Scholar
• MarderSREssockSMMillerALPhysical health monitoring of patients with schizophreniaAm J Psychiatry20041611334134915285957
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry200416115615000267
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of ObesityConsensus development conference on antipsychotic drugs and obesity and diabetesDiabetes Care20042759660114747245
   PubMed Web of Science ®Google Scholar
• MeyerJMAntipsychotics and metabolics in the post-CATIE eraCurr Top Behav Neurosci20104234221312396
   PubMedGoogle Scholar
• LeuchtSCiprianiLSpineliLComparative efficacy and toler-ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet201338295196223810019
   PubMed Web of Science ®Google Scholar
• CitromeLJohnstonSNadkarniASheehanJJKamatSAKalsekarIPrevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and Medicaid insured patients newly initiating atypical antipsychoticsCurr Drug Saf2014922723524909573
   PubMedGoogle Scholar
• KennedyWKJannMWKutscherECClinically significant drug interactions with atypical antipsychoticsCNS Drugs2013271021104824170642
   PubMed Web of Science ®Google Scholar
• KellerWRFischerBAMcMahonRCommunity adherence to schizophrenia treatment and safety monitoring guidelinesJ Nerv Ment Dis201420261224375205
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• GardnerKNBostwickJRAntipsychotic treatment response in schizophreniaAm J Health Syst Pharm2012691872187923111671
   PubMed Web of Science ®Google Scholar
• TargumSDPestreichLReksoprodjoPPereiraHGuindonCHochfeldMA global measure to assess switching antipsychotic medications in the treatment of schizophreniaHum Psychopharmacol20122745546322826027
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corp. Clozaril (clozapine) Available from: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdfAccessed May 11, 2015
   Google Scholar
• CitromeLNasrallahHAOn-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does notExpert Opin Pharmacother201213111599161322017361
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LPSeroquel (quetiapine) Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdfAccessed March 6, 2015
   Google Scholar
• Eli Lilly and CompanyZyprexa (olanzapine) Available from: http://pi.lilly.com/us/zyprexa-pi.pdfAccessed March 6, 2015
   Google Scholar
• Forest Pharmaceutical IncSaphris (asenapine) Available from: http://pi.actavis.com/data_stream.asp?product_group=1908&p=pi&language=EAccessed March 6, 2015
   Google Scholar
• Janssen Pharmaceuticals IncInvega (paliperidone) Available from: http://www.janssencns.com/sites/default/files/pdf/invega/invega.pdfAccessed March 17, 2015
   Google Scholar
• Janssen Pharmaceuticals IncRisperdal (risperidone) Available from: http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdfAccessed March 6, 2015
   Google Scholar
• Novartis Pharmaceuticals CorpFanapt (iloperidone) Available from: http://www.fanapt.com/product/pi/pdf/fanapt.pdfAccessed March 10, 2015
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd.Abilify (aripiprazole) Available from: http://www.otsuka-us.com/Documents/Abilify.PI.pdfAccessed March 6, 2015
   Google Scholar
• Pfizer, IncGeodon (ziprasidone) Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=584Accessed March 6, 2015
   Google Scholar
• Sunovion Pharmaceuticals IncLatuda (lurasidone hydrochloride) Available from: http://www.latuda.com/LatudaPrescribingInformation.pdfAccessed March 10, 2015
   Google Scholar
• MitchellAJVancampfortDDe HerdtAYuWDe HertMIs the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first-episode, untreated and treated patientsSchizophr Bull20133929530522927670
   PubMed Web of Science ®Google Scholar
• ViertioSTuulio-HenrikssonAPeralaJActivities of daily living, social functioning and their determinants in persons with psychotic disorderEur Psychiatry20122740941521377336
   PubMed Web of Science ®Google Scholar
• PapageorgiouGCanasFZinkMRossiACountry differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in EuropeEur Psychiatry201126172821440220
   PubMed Web of Science ®Google Scholar
• MillierAAmriIBoyerLAuquierPToumiMUtility decrements associated with side effects in schizophreniaJ Med Econ20141785386125211094
   PubMedGoogle Scholar
• OzekiYFujiiKKurimotoQTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry20103440140520079791
   PubMed Web of Science ®Google Scholar
• YangFDWangXQLiuXPSex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychoticsPsychopharmacology (Berl)201121691621301815
   PubMed Web of Science ®Google Scholar
• Riechler-RosslerARybakowskiJKPfluegerMOHyperpro-lactemia in antipsychotic-naïve patients with first-episode psychosisPsychol Med2013432571258223590895
   PubMed Web of Science ®Google Scholar
• BusheCShawMPrevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychoticsJ Psychopharmacol20072176877317606473
   PubMed Web of Science ®Google Scholar
• KinonBJLiu-SeifertHStaufferVLJacobJBone loss associated with hyperprolactinemia in patients with schizophreniaClin Schiz Related Psychoses201373115123
   PubMedGoogle Scholar
• StubbsBDe HertMSepehryAAA meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophreniaActa Psychiatr Scand2014130647048625041606
   PubMed Web of Science ®Google Scholar
• KarthikMSKulharaPChakrabartiSAttitude towards second-generation antipsychotics among patients with schizophrenia and their relativesHum Psychopharmacol20132845746523784674
   PubMed Web of Science ®Google Scholar
• BaggaleyMSexual dysfunction in schizophrenia: focus on recent evidenceHum Psychopharmacol20082320120918338766
   PubMed Web of Science ®Google Scholar
• Abdel-BakiALetourneauGMorinCNgAResumption of work or studies after first episode psychosis: the impact of vocational case managementEarly Interv Psychiatry2013739139823347401
   PubMed Web of Science ®Google Scholar
• MeltzerHYOutcome in schizophrenia: beyond symptom reductionJ Clin Psychiatry199960310073370
   PubMed Web of Science ®Google Scholar
• VargasGStrassnigMSabbagSThe course of vocational functioning in patients with schizophrenia: re-examining social driftSchizophr Res Cogn201414146
   Google Scholar
• HaroJMNovickDPerrinEBertschJKnappMSymptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship?Psychiatry Res201422016316925194449
   PubMed Web of Science ®Google Scholar
• WatersFNaikNRockDSleep, fatigue, and functional health in psychotic patientsSchizophr Res Treatment2013201342582623738067
   PubMedGoogle Scholar
• PeraltaVde JalonEGCamposMSCuestaMJPhenomenological differences between spontaneous and drug-related extrapyramidal syndromes in patients with schizophrenia-spectrum disordersJ Clin Psychopharm201333438440
   Web of Science ®Google Scholar
• KaneJMFleischhackerWWHansenLPerlisRPikalovA3rdAssunção-TalbottSAkathisia: an updated review focusing on second-generation antipsychoticsJ Clin Psychiatry20097062764319389331
   PubMed Web of Science ®Google Scholar
• CitromeLA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approachCNS Drugs2013271187991124062193
   PubMed Web of Science ®Google Scholar
• VolavkaJCitromeLOral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-makingExpert Opin Pharmacother200910121917192819558339
   PubMed Web of Science ®Google Scholar
• CitromeLKalsekarIBakerRAHebdenTA review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adultsCurr Med Res Opin2014301629164124666104
   PubMed Web of Science ®Google Scholar
• LasicDBevandaMBosnjakNUglešićBGlavinaTFranićTMetabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorderPsychiatr Danub20142621421925191767
   PubMed Web of Science ®Google Scholar
• KucerovaJBabinskaZHorskaKKotolovaHThe common pathophysiology underlying the metabolic syndrome, schizophrenia, and depression: a reviewBiomed Pap Med Fac Univ Palacky Olomourc Czech Repub20151592208214
   PubMed Web of Science ®Google Scholar
• RojoLEGasparPASilvaHMetabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacologyPharmacol Res Epub2015725
   Web of Science ®Google Scholar
• LeungJYBarrAMProcyshynRMHonerWGPangCCCardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous systemPharmacol Ther2012135211312222565090
   PubMed Web of Science ®Google Scholar
• HasnainMViewegWVQTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive reviewCNS Drugs2014281088792025168784
   PubMed Web of Science ®Google Scholar
• De HertMDetrauxJPeuskensJSecond-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature reviewExpert Opin Drug Saf201413560562424697217
   PubMed Web of Science ®Google Scholar
• PeuskensJPaniLDetrauxJDe HertMThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive reviewCNS Drugs201428542145324677189
   PubMed Web of Science ®Google Scholar
• BargiotaSIBonotisKSMessinisIEAngelopoulosNVThe effects of antipsychotics on prolactin levels and women’s menstruationSchizophr Res Treatment2013201350269724490071
   PubMedGoogle Scholar
• JustMJThe influence of atypical antipsychotic drugs on sexual functionNeuropsychiatr Dis Treat2015111655166126185449
   PubMed Web of Science ®Google Scholar
• GaoKGanocySJGajwaniPMuzinaDJKempDECalabreseJRA review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolenceJ Clin Psychiatry200869230230918211129
   PubMed Web of Science ®Google Scholar
• BrattiIMKaneJMMarderSRChronic restlessness with antipsychot-icsAm J Psychiatry2007164111648165417974927
   PubMed Web of Science ®Google Scholar
• PelusoMJLewisSWBarnesTRJonesPBExtrapyramidal motor side-effects of first- and second-generation antipsychotic drugsBr J Psychiatry2012200538739222442101
   PubMed Web of Science ®Google Scholar
• ShayeganDKStahlSMAtypical antipsychotics: matching receptor profile to individual patient’s clinical profileCNS Spectr2004910 Suppl 1161415475871
   PubMed Web of Science ®Google Scholar
• DarganiNVMalhotraAKSafety profile of iloperidone in the treatment of schizophreniaExpert Opin Drug Saf201413224124624206391
   PubMed Web of Science ®Google Scholar
• StahlSMRole of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptomsCNS Spectr201318628528824300463
   PubMed Web of Science ®Google Scholar
• Matsui-SakataAOhtaniHSawadaYReceptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitusDrug Metab Pharmacokinet200520536837816272755
   PubMedGoogle Scholar
• StahlSMStahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications4th edCambridgeCambridge University Press2013
   Google Scholar